cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.48597/k659-bgft
title: Measurement of Mercury at Vavihill

description: Measurement of Mercury at Vavihill
DOI: 10.48597/kkr2-k72y
title: Measurement of Zinc at Auchencorth Moss

description: Measurement of Zinc at Auchencorth Moss
DOI: 10.48597/ks9s-c39w
title: Measurement of Strontium at Harwell

description: Measurement of Strontium at Harwell
DOI: 10.48597/m3a8-uakp
title: Measurement of Uranium at Auchencorth Moss

description: Measurement of Uranium at Auchencorth Moss
DOI: 10.48597/m79w-w9ye
title: Measurement of Mercury at Niembro

description: Measurement of Mercury at Niembro
DOI: 10.48597/mfd5-qhpa
title: Measurement of Zinc at Harwell

description: Measurement of Zinc at Harwell
DOI: 10.48597/mguk-vs7n
title: Measurement of Arsenic at Harwell

description: Measurement of Arsenic at Harwell
DOI: 10.48597/n839-pwpu
title: Measurement of Mercury at Waldhof

description: Measurement of Mercury at Waldhof
DOI: 10.48597/nh37-tq5h
title: Measurement of Zinc at San Pablo de los Montes

description: Measurement of Zinc at San Pablo de los Montes
DOI: 10.48597/nh9y-pj8h
title: Measurement of Titanium at Harwell

description: Measurement of Titanium at Harwell
DOI: 10.48597/nrtf-wbuc
title: Measurement of Antimony at Harwell

description: Measurement of Antimony at Harwell
DOI: 10.48597/pekb-fsje
title: Measurement of Cadmium at Harwell

description: Measurement of Cadmium at Harwell
DOI: 10.48597/q8g7-nejh
title: Measurement of Arsenic at Vavihill

description: Measurement of Arsenic at Vavihill
DOI: 10.48597/q8zp-8kkk
title: Measurement of Heavy metals at Anholt

description: Measurement of Heavy metals at Anholt
DOI: 10.48597/quej-b5vg
title: Measurement of Arsenic at Víznar

description: Measurement of Arsenic at Víznar
DOI: 10.48597/r3vp-bcqj
title: Measurement of Iron at Vavihill

description: Measurement of Iron at Vavihill
DOI: 10.48597/rnh6-4wbe
title: Measurement of Arsenic at Niembro

description: Measurement of Arsenic at Niembro
DOI: 10.48597/rz2x-dahy
title: Measurement of Cadmium at Vavihill

description: Measurement of Cadmium at Vavihill
DOI: 10.48597/s2xb-xvxv
title: Measurement of Mercury at Harwell

description: Measurement of Mercury at Harwell
DOI: 10.48597/swhs-pyex
title: Measurement of Barium at Harwell

description: Measurement of Barium at Harwell
DOI: 10.48597/t6v8-hrbh
title: Measurement of Selenium at Auchencorth Moss

description: Measurement of Selenium at Auchencorth Moss
DOI: 10.48597/td49-684d
title: Measurement of Mercury at Pallas (Matorova)

description: Measurement of Mercury at Pallas (Matorova)
DOI: 10.48597/tfy6-rffs
title: Measurement of Mercury at San Pablo de los Montes

description: Measurement of Mercury at San Pablo de los Montes
DOI: 10.48597/tq8z-3242
title: Measurement of Heavy metals at K-puszta

description: Measurement of Heavy metals at K-puszta
DOI: 10.48597/u23w-7w7e
title: Measurement of Vanadium at Harwell

description: Measurement of Vanadium at Harwell
DOI: 10.48597/u3du-mc3a
title: Measurement of Molybdenum at Harwell

description: Measurement of Molybdenum at Harwell
DOI: 10.48597/v9tz-52fr
title: Measurement of Uranium at Harwell

description: Measurement of Uranium at Harwell
DOI: 10.48597/vveg-hnm2
title: Measurement of Copper at Harwell

description: Measurement of Copper at Harwell
DOI: 10.48597/vxwm-hyev
title: Measurement of Arsenic at Auchencorth Moss

description: Measurement of Arsenic at Auchencorth Moss
DOI: 10.48597/vyzf-y4hh
title: Measurement of Selenium at Harwell

description: Measurement of Selenium at Harwell
DOI: 10.48597/whvx-qxku
title: Measurement of Molybdenum at Auchencorth Moss

description: Measurement of Molybdenum at Auchencorth Moss
DOI: 10.17909/ym0y-s612
title: HST UV Spectroscopy of SN 2023tsz
DOI: 10.48597/wpjv-qbmz
title: Measurement of Barium at Auchencorth Moss

description: Measurement of Barium at Auchencorth Moss
DOI: 10.48597/wqj7-5pzx
title: Measurement of Chromium at San Pablo de los Montes

description: Measurement of Chromium at San Pablo de los Montes
DOI: 10.48597/wudj-h6uw
title: Measurement of Lead at Auchencorth Moss

description: Measurement of Lead at Auchencorth Moss
DOI: 10.15468/dl.3fpvac
title: Occurrence Download

description: A dataset containing 12 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Thymus dolopicus Formánek"
 ]
}

 The dataset includes 12 records from 8 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0127618-240321170329656/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.25398643.v2
title: Supplementary Material for: Safety and Tolerability of the APOL1 Inhibitor, Inaxaplin, Following Single- and Multiple-ascending Doses in Healthy Adults

description: Introduction
Toxic gain-of-function Apolipoprotein L1 (APOL1) variants contribute to the development of proteinuric nephropathies collectively referred to as APOL1-mediated kidney disease (AMKD). Despite standard-of-care treatments, patients with AMKD experience accelerated progression to end stage kidney disease. The identification of two APOL1 variants as the genetic cause of AMKD inspired development of inaxaplin, an inhibitor of APOL1 channel activity that reduces proteinuria in patients with AMKD.

Methods
We conducted two phase 1 studies evaluating the safety, tolerability, and pharmacokinetics of single-ascending doses (SAD) and multiple-ascending doses (MAD) of inaxaplin in healthy participants. In the SAD cohorts, participants were randomized to receive inaxaplin as a single dose (range, 7.5 mg to 165 mg) or placebo. In the MAD cohorts, participants were randomized to receive multiple doses of inaxaplin (range, 15 to 120 mg daily) or placebo for 14 days. We assessed safety and tolerability based on adverse events (AEs), clinical laboratory values, electrocardiograms (ECGs), and vital signs.

Results
A total of 178 participants were randomized in the SAD/MAD cohorts of both studies (mean age: 36.7 years; 94.9% male). The proportion of participants with any AEs was similar in the inaxaplin (24.6%) and placebo (22.7%) groups. All AEs were mild or moderate in severity; there were no serious AEs. Headache was the most common AE: 10.4% and 2.3% in the inaxaplin and placebo groups, respectively. There were no drug-related treatment discontinuations and no clinically relevant trends in laboratory values, ECGs, or vital signs.

Discussion/Conclusion
Inaxaplin is safe and well tolerated at single doses up to 165 mg and multiple doses up to 120 mg daily for 14 days. These results are consistent with the favorable safety profile of inaxaplin in a completed phase 2a proof-of-concept study. Together, these findings support continued evaluation of inaxaplin in an ongoing phase 2/3 pivotal trial as a potential precision medicine for patients with AMKD.
DOI: 10.15468/dl.nf927a
title: Occurrence Download

description: A dataset containing 77 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Vaccinium halconense Merr."
 ]
}

 The dataset includes 77 records from 15 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0127617-240321170329656/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.25398643.v3
title: Supplementary Material for: Safety and Tolerability of the APOL1 Inhibitor, Inaxaplin, Following Single- and Multiple-ascending Doses in Healthy Adults

description: Introduction
Toxic gain-of-function Apolipoprotein L1 (APOL1) variants contribute to the development of proteinuric nephropathies collectively referred to as APOL1-mediated kidney disease (AMKD). Despite standard-of-care treatments, patients with AMKD experience accelerated progression to end stage kidney disease. The identification of two APOL1 variants as the genetic cause of AMKD inspired development of inaxaplin, an inhibitor of APOL1 channel activity that reduces proteinuria in patients with AMKD.

Methods
We conducted two phase 1 studies evaluating the safety, tolerability, and pharmacokinetics of single-ascending doses (SAD) and multiple-ascending doses (MAD) of inaxaplin in healthy participants. In the SAD cohorts, participants were randomized to receive inaxaplin as a single dose (range, 7.5 mg to 165 mg) or placebo. In the MAD cohorts, participants were randomized to receive multiple doses of inaxaplin (range, 15 to 120 mg daily) or placebo for 14 days. We assessed safety and tolerability based on adverse events (AEs), clinical laboratory values, electrocardiograms (ECGs), and vital signs.

Results
A total of 178 participants were randomized in the SAD/MAD cohorts of both studies (mean age: 36.7 years; 94.9% male). The proportion of participants with any AEs was similar in the inaxaplin (24.6%) and placebo (22.7%) groups. All AEs were mild or moderate in severity; there were no serious AEs. Headache was the most common AE: 10.4% and 2.3% in the inaxaplin and placebo groups, respectively. There were no drug-related treatment discontinuations and no clinically relevant trends in laboratory values, ECGs, or vital signs.

Discussion/Conclusion
Inaxaplin is safe and well tolerated at single doses up to 165 mg and multiple doses up to 120 mg daily for 14 days. These results are consistent with the favorable safety profile of inaxaplin in a completed phase 2a proof-of-concept study. Together, these findings support continued evaluation of inaxaplin in an ongoing phase 2/3 pivotal trial as a potential precision medicine for patients with AMKD.
DOI: 10.6084/m9.figshare.25398643.v4
title: Supplementary Material for: Safety and Tolerability of the APOL1 Inhibitor, Inaxaplin, Following Single- and Multiple-ascending Doses in Healthy Adults

description: Introduction
Toxic gain-of-function Apolipoprotein L1 (APOL1) variants contribute to the development of proteinuric nephropathies collectively referred to as APOL1-mediated kidney disease (AMKD). Despite standard-of-care treatments, patients with AMKD experience accelerated progression to end stage kidney disease. The identification of two APOL1 variants as the genetic cause of AMKD inspired development of inaxaplin, an inhibitor of APOL1 channel activity that reduces proteinuria in patients with AMKD.

Methods
We conducted two phase 1 studies evaluating the safety, tolerability, and pharmacokinetics of single-ascending doses (SAD) and multiple-ascending doses (MAD) of inaxaplin in healthy participants. In the SAD cohorts, participants were randomized to receive inaxaplin as a single dose (range, 7.5 mg to 165 mg) or placebo. In the MAD cohorts, participants were randomized to receive multiple doses of inaxaplin (range, 15 to 120 mg daily) or placebo for 14 days. We assessed safety and tolerability based on adverse events (AEs), clinical laboratory values, electrocardiograms (ECGs), and vital signs.

Results
A total of 178 participants were randomized in the SAD/MAD cohorts of both studies (mean age: 36.7 years; 94.9% male). The proportion of participants with any AEs was similar in the inaxaplin (24.6%) and placebo (22.7%) groups. All AEs were mild or moderate in severity; there were no serious AEs. Headache was the most common AE: 10.4% and 2.3% in the inaxaplin and placebo groups, respectively. There were no drug-related treatment discontinuations and no clinically relevant trends in laboratory values, ECGs, or vital signs.

Discussion/Conclusion
Inaxaplin is safe and well tolerated at single doses up to 165 mg and multiple doses up to 120 mg daily for 14 days. These results are consistent with the favorable safety profile of inaxaplin in a completed phase 2a proof-of-concept study. Together, these findings support continued evaluation of inaxaplin in an ongoing phase 2/3 pivotal trial as a potential precision medicine for patients with AMKD.
DOI: 10.6084/m9.figshare.25398643
title: Supplementary Material for: Safety and Tolerability of the APOL1 Inhibitor, Inaxaplin, Following Single- and Multiple-ascending Doses in Healthy Adults

description: Introduction
Toxic gain-of-function Apolipoprotein L1 (APOL1) variants contribute to the development of proteinuric nephropathies collectively referred to as APOL1-mediated kidney disease (AMKD). Despite standard-of-care treatments, patients with AMKD experience accelerated progression to end stage kidney disease. The identification of two APOL1 variants as the genetic cause of AMKD inspired development of inaxaplin, an inhibitor of APOL1 channel activity that reduces proteinuria in patients with AMKD.

Methods
We conducted two phase 1 studies evaluating the safety, tolerability, and pharmacokinetics of single-ascending doses (SAD) and multiple-ascending doses (MAD) of inaxaplin in healthy participants. In the SAD cohorts, participants were randomized to receive inaxaplin as a single dose (range, 7.5 mg to 165 mg) or placebo. In the MAD cohorts, participants were randomized to receive multiple doses of inaxaplin (range, 15 to 120 mg daily) or placebo for 14 days. We assessed safety and tolerability based on adverse events (AEs), clinical laboratory values, electrocardiograms (ECGs), and vital signs.

Results
A total of 178 participants were randomized in the SAD/MAD cohorts of both studies (mean age: 36.7 years; 94.9% male). The proportion of participants with any AEs was similar in the inaxaplin (24.6%) and placebo (22.7%) groups. All AEs were mild or moderate in severity; there were no serious AEs. Headache was the most common AE: 10.4% and 2.3% in the inaxaplin and placebo groups, respectively. There were no drug-related treatment discontinuations and no clinically relevant trends in laboratory values, ECGs, or vital signs.

Discussion/Conclusion
Inaxaplin is safe and well tolerated at single doses up to 165 mg and multiple doses up to 120 mg daily for 14 days. These results are consistent with the favorable safety profile of inaxaplin in a completed phase 2a proof-of-concept study. Together, these findings support continued evaluation of inaxaplin in an ongoing phase 2/3 pivotal trial as a potential precision medicine for patients with AMKD.
DOI: 10.6084/m9.figshare.25398643.v6
title: Supplementary Material for: Safety and Tolerability of the APOL1 Inhibitor, Inaxaplin, Following Single- and Multiple-ascending Doses in Healthy Adults

description: Introduction
Toxic gain-of-function Apolipoprotein L1 (APOL1) variants contribute to the development of proteinuric nephropathies collectively referred to as APOL1-mediated kidney disease (AMKD). Despite standard-of-care treatments, patients with AMKD experience accelerated progression to end stage kidney disease. The identification of two APOL1 variants as the genetic cause of AMKD inspired development of inaxaplin, an inhibitor of APOL1 channel activity that reduces proteinuria in patients with AMKD.

Methods
We conducted two phase 1 studies evaluating the safety, tolerability, and pharmacokinetics of single-ascending doses (SAD) and multiple-ascending doses (MAD) of inaxaplin in healthy participants. In the SAD cohorts, participants were randomized to receive inaxaplin as a single dose (range, 7.5 mg to 165 mg) or placebo. In the MAD cohorts, participants were randomized to receive multiple doses of inaxaplin (range, 15 to 120 mg daily) or placebo for 14 days. We assessed safety and tolerability based on adverse events (AEs), clinical laboratory values, electrocardiograms (ECGs), and vital signs.

Results
A total of 178 participants were randomized in the SAD/MAD cohorts of both studies (mean age: 36.7 years; 94.9% male). The proportion of participants with any AEs was similar in the inaxaplin (24.6%) and placebo (22.7%) groups. All AEs were mild or moderate in severity; there were no serious AEs. Headache was the most common AE: 10.4% and 2.3% in the inaxaplin and placebo groups, respectively. There were no drug-related treatment discontinuations and no clinically relevant trends in laboratory values, ECGs, or vital signs.

Discussion/Conclusion
Inaxaplin is safe and well tolerated at single doses up to 165 mg and multiple doses up to 120 mg daily for 14 days. These results are consistent with the favorable safety profile of inaxaplin in a completed phase 2a proof-of-concept study. Together, these findings support continued evaluation of inaxaplin in an ongoing phase 2/3 pivotal trial as a potential precision medicine for patients with AMKD.
DOI: 10.6084/m9.figshare.25398643.v5
title: Supplementary Material for: Safety and Tolerability of the APOL1 Inhibitor, Inaxaplin, Following Single- and Multiple-ascending Doses in Healthy Adults

description: Introduction
Toxic gain-of-function Apolipoprotein L1 (APOL1) variants contribute to the development of proteinuric nephropathies collectively referred to as APOL1-mediated kidney disease (AMKD). Despite standard-of-care treatments, patients with AMKD experience accelerated progression to end stage kidney disease. The identification of two APOL1 variants as the genetic cause of AMKD inspired development of inaxaplin, an inhibitor of APOL1 channel activity that reduces proteinuria in patients with AMKD.

Methods
We conducted two phase 1 studies evaluating the safety, tolerability, and pharmacokinetics of single-ascending doses (SAD) and multiple-ascending doses (MAD) of inaxaplin in healthy participants. In the SAD cohorts, participants were randomized to receive inaxaplin as a single dose (range, 7.5 mg to 165 mg) or placebo. In the MAD cohorts, participants were randomized to receive multiple doses of inaxaplin (range, 15 to 120 mg daily) or placebo for 14 days. We assessed safety and tolerability based on adverse events (AEs), clinical laboratory values, electrocardiograms (ECGs), and vital signs.

Results
A total of 178 participants were randomized in the SAD/MAD cohorts of both studies (mean age: 36.7 years; 94.9% male). The proportion of participants with any AEs was similar in the inaxaplin (24.6%) and placebo (22.7%) groups. All AEs were mild or moderate in severity; there were no serious AEs. Headache was the most common AE: 10.4% and 2.3% in the inaxaplin and placebo groups, respectively. There were no drug-related treatment discontinuations and no clinically relevant trends in laboratory values, ECGs, or vital signs.

Discussion/Conclusion
Inaxaplin is safe and well tolerated at single doses up to 165 mg and multiple doses up to 120 mg daily for 14 days. These results are consistent with the favorable safety profile of inaxaplin in a completed phase 2a proof-of-concept study. Together, these findings support continued evaluation of inaxaplin in an ongoing phase 2/3 pivotal trial as a potential precision medicine for patients with AMKD.
DOI: 10.15468/dl.vxqvzp
title: Occurrence Download

description: A dataset containing 28245689 species occurrences available in GBIF matching the query:
{
 "Country" : [
 "is Colombia"
 ]
}

 The dataset includes 28245689 records from 4570 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0127571-240321170329656/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.jks7k7
title: Occurrence Download

description: A dataset containing 1 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Alburnoides economoui)",
 "BasisOfRecord is one of (Specimen, Literature Occurrence, Human Observation, Observation)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "Year is greater than or equal to 1991",
 "Year is less than or equal to 2025"
 ]
}

 The dataset includes 1 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0024787-250827131500795/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.16902866
title: National Exposure Model for Industrial Structures in Chile

description: Database corresponding to the article "Exposure Model for Industrial Structures in Chile"Filtered and corrected database containing the number and geographic location of industrial structures present in Chile.
DOI: 10.5281/zenodo.16902867
title: National Exposure Model for Industrial Structures in Chile

description: Database corresponding to the article "Exposure Model for Industrial Structures in Chile"Filtered and corrected database containing the number and geographic location of industrial structures present in Chile.
DOI: 10.15468/dl.vq9x7k
title: Occurrence Download

description: A dataset containing 170 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((-30 81, 50 81, 50 12, -30 12, -30 81))",
 "HasCoordinate is true",
 "BasisOfRecord is one of (Observation, Machine Observation, Human Observation, Material sample, Living Specimen, Occurrence evidence)",
 "TaxonKey is one of (Emplectonema gracile)"
 ]
}

 The dataset includes 170 records from 17 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0024788-250827131500795/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.xyb6pj
title: Occurrence Download

description: A dataset containing 167 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Grewia tomentosa"
 ]
}

 The dataset includes 167 records from 13 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0024789-250827131500795/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.njhkhf
title: Occurrence Download

description: A dataset containing 55 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Pseudomugil mellis"
 ]
}

 The dataset includes 55 records from 11 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0024792-250827131500795/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.bvy7w4
title: Occurrence Download

description: A dataset containing 18 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Atriplex prostrata",
 "Country is Belarus",
 "HasCoordinate is true"
 ]
}

 The dataset includes 18 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0024794-250827131500795/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.qmc9us
title: Occurrence Download

description: A dataset containing 2931 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Atriplex prostrata",
 "Country is Australia",
 "HasCoordinate is true"
 ]
}

 The dataset includes 2931 records from 32 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0024793-250827131500795/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.